We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+5.37%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$68.2M
Cap. Flow
+$46.3M
Cap. Flow %
2.39%
Top 10 Hldgs %
80.83%
Holding
24
New
1
Increased
6
Reduced
8
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$13.9M
3
HALO icon
Halozyme
HALO
+$13.6M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.55M
5
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$7.51M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$9.47M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.62M
3
INCY icon
Incyte
INCY
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$4.77M
5
GILD icon
Gilead Sciences
GILD
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 87.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$305M 15.72%
4,369,298
+310,756
+8% +$24.6M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.4B
$272M 14.04%
6,301,526
-116,022
-2% -$5.62M
GILD icon
3
Gilead Sciences
GILD
$165B
$249M 12.83%
3,513,496
-34,218
-1% -$2.68M
INCY icon
4
Incyte
INCY
$24.4B
$221M 11.4%
4,133,790
-87,297
-2% -$5.42M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$111M 5.7%
727,428
-30,000
-4% -$4.77M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$126B
$99.3M 5.12%
1,404,445
– –
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$94M 4.84%
2,919,412
-40,000
-1% -$1.48M
GEVA
8
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$78M 4.02%
939,957
+81,200
+9% +$7.51M
HALO icon
9
Halozyme
HALO
$12.2B
$71.7M 3.69%
5,641,564
+916,628
+19% +$13.6M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$80.8B
$67M 3.45%
223,000
+31,000
+16% +$9.55M
PCYC
11
DELISTED
PHARMACYCLICS INC
PCYC
$63.8M 3.29%
636,542
– –
ECYT
12
DELISTED
Endocyte, Inc. Common Stock
ECYT
$58.7M 3.02%
2,463,522
-180,000
-7% -$2.61M
NBIX icon
13
Neurocrine Biosciences
NBIX
$16.6B
$48.2M 2.49%
2,996,552
+350,000
+13% +$5.99M
IMGN
14
DELISTED
Immunogen Inc
IMGN
$47.3M 2.44%
3,165,816
-60,000
-2% -$946K
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$33.8M 1.74%
488,188
– –
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.3B
$31.6M 1.63%
471,288
– –
INVA icon
17
Innoviva
INVA
$1.48B
$27.5M 1.42%
1,102,311
– –
TSRO
18
DELISTED
TESARO, Inc.
TSRO
$17.8M 0.92%
604,582
+133,300
+28% +$4.2M
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$15.5M 0.8%
1,300,737
– –
PBYI icon
20
Puma Biotechnology
PBYI
$454M
$12.3M 0.63%
+117,991
New +$13.9M
IDIX
21
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$7.54M 0.39%
1,250,000
– –
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
$5.85M 0.3%
1,779,340
– –
ARIA
23
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.38M 0.07%
171,517
-1,215,654
-88% -$9.47M

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2014 Portfolio in Review

As of Q1 2014, BB Biotech held 24 positions worth $1.94B, up 3.6% from $1.87B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Trading was light in Q1 2014: portfolio turnover was 4.2%. BB Biotech opened 1 new position and made no exits, leaving the 24-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier.

  • BB Biotech's largest Q1 2014 buy was Puma Biotechnology: 117,991 shares worth $12.3M.
  • BB Biotech added most to Celgene Corp in Q1 2014, an estimated $24.6M increase.
  • BB Biotech's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $9.47M.
  • BB Biotech's ten largest holdings make up 81% of its $1.94B portfolio in Q1 2014.
  • BB Biotech opened 1 new position and closed 0 in Q1 2014.
  • BB Biotech's portfolio value rose 3.6% quarter-over-quarter to $1.94B.

Based on BB Biotech's 13F filing for Q1 2014, filed 8 May 2014.